Data-Driven Insights
September 26, 2018 | Brandon Underwood
The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is taken from the Q&A session of IntegriChain's recent 340B webinar. Topics discussed include growth in contract pharmacies/covered entities, 340B discount pricing for orphan drugs, and validation of 340B entities.
August 20, 2018 | Shivani Patel
The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharmaceutical manufacturers are now facing increased scrutiny and need new approaches to monitor and report on irregular order patterns for controlled substances. This post discusses a new approach that provides visibility across pharmacy locations and wholesale distributors while weaving in additional demographic insights.
August 3, 2018 | Sean McCarthy
There are several ways specialty brands can improve patient initiation by implementing data-driven patient support strategies. Successful interventions to streamline patient initiation have the potential to speed Time to First Fill and increase overall Fill Rate for new patient referrals. Each key opportunity to improve patient initiation is related to a friction point in the patient journey. In this post, IntegriChain Patient Access Segment Leader Sean McCarthy provides an overview of these key opportunities and the potential of analytics to unlock efficiencies for specialty brands.
July 27, 2018 | David Carlson
Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these products account for an ever increasing share of overall pharmaceutical sales. The Payer community is reaching for value as per patient costs rise. This post discusses value-based contracts as a mutually beneficial solution for Payers and pharmaceutical manufacturers and the meaningful role analytics can play in executing and managing these innovative agreements.
March 21, 2017 | Brandon Underwood
Brandon Underwood offers a sneak peek at IntegriChain's upcoming Specialty Analytics benchmark report. IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory. Overall, IntegriChain and ProMetrics analyzed more than 657,000 sub-status records reported in Q4 2016. The brands we studied had comparable status/sub-status reporting requirements.
June 2, 2016 | Sunay Shah
In my last post, I explored how IntegriChain Scorecard Analytics can be used to validate whether the implementation of Distribution Service Agreements (DSAs) drives channel performance. In this post, we will deep dive with a step-by-step approach outlining how Scorecard Analytics can be leverage to optimize changes to DSAs. First, let’s look at the metrics. DSA metrics come in two basic flavors – performance and data transmission The performance metrics are typically composed of a service level metric, purchase stability (or demand variability) metric, and an inventory level metric. The data transmission metrics are typically composed of data delivery timeliness, completeness, and […]
May 27, 2016 | Colleen Hallett
The Asembia (formerly known as Armada) Specialty Pharmacy Summit is fast becoming the pharmaceutical industry’s most important meeting. This year’s Las Vegas show boasted a record attendance of nearly 5,000 pharmaceutical manufacturers, specialty pharmacies, payers, and solution vendors. As new therapies trend more and more towards high price, niche, or patient-tailored treatments often requiring special handling, this surge of interest in all things specialty pharmacy is no surprise. The enormous rise in specialty brand launches has changed the traditional channel distribution model. Life sciences distribution channels have become much more complicated, and this has led to an increase in the number […]
April 6, 2016 | Sunay Shah
Distribution Service Agreements (DSAs) have continued to evolve over recent years especially as they relate to how they evaluate channel performance. For the most part, manufacturers structure the agreements to ensure trade partners effectively and efficiently fulfill downstream orders, manage volatility of orders, maintain appropriate inventory level (as defined by manufacturer), and transmit data to manufacturers. As the industry matures in how DSAs are structured, we are seeing trends of new concepts such as misses being incorporated into agreements. However, what is very interesting is how much the industry has validated the efficacy of DSAs. Even as the agreements are […]
March 2, 2016 | Dave Weiss
By now, government price departments are well underway towards implementing the Final Average Manufacturer Price (AMP) Rule recently issued by the Center of Medicare and Medicaid Services (CMS). AMP is the average manufacturer price paid by retail community pharmacies (RCP). One of the key provisions of the sub-regulatory guidance is related to “5i” drugs (i.e., infused, injected, implanted, inhaled, or instilled drugs) that are drugs that are “not generally dispensed“ (NGD) in retail pharmacies but rather at infusion centers, specialty pharmacies, and so on. Even though 5i drugs are not sold into retail, they still require an AMP for other […]
March 1, 2016 | Kevin Leininger
Today we announced an equity partnership with Accel-KKR (AKKR) that is very exciting both for IntegriChain and our customers. Both IntegriChain and AKKR share a singular vision to service underserved constituencies in the life sciences industry. Life sciences companies are facing a rapidly evolving marketplace driven by changes across the entire healthcare ecosystem from providers to payers and distribution platforms. Navigating this requires life sciences companies to completely rethink the way they advance and support the patient journey. The days of primary care physicians and retail pharmacies serving branded, pill-based prescription products shipped once per week from wholesalers across the […]